by Holly Vernyi | Dec 24, 2025 | Uncategorized
In this interview Ira Zackon, MD, highlights data on bispecific antibody use in patients with multiple myeloma in the community setting as presented at ASH 2025.Zackon noted that the retrospective observational study included representation of Black Americans and...
by MM360 Staff | Dec 24, 2025 | Myeloma News
Source: Pharmacy Times articles Post Content Read More
by Marisa Wexler, MS | Dec 23, 2025 | Myeloma News
VV169, an experimental cellular therapy being developed by Vyriad to treat myeloma, is expected to enter clinical testing in 2026, the company announced. Earlier this month at the 67th annual meeting of the American Society of Hematology (ASH), Vyriad presented...
by MM360 Staff | Dec 23, 2025 | Myeloma News
Source: Myeloma : nature.com subject feeds Post Content Read More
by MM360 Staff | Dec 23, 2025 | Myeloma News
Source: Myeloma : nature.com subject feeds Post Content Read More
